Tenax Therapeutics Issued U.S. Patent For Oral Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction (PH-HFpEF)
Portfolio Pulse from Benzinga Newsdesk
Tenax Therapeutics has been granted a U.S. patent for oral Levosimendan in the treatment of pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF), a condition affecting over 1.6 million North Americans. The patent provides intellectual property protection until December 2040 and may qualify for term extension beyond 2040. The company plans to initiate a Phase 3 trial using TNX-103 (oral levosimendan) in 2023.

July 19, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The new patent for Tenax Therapeutics' oral Levosimendan could potentially open up a large market, as there are currently no FDA-approved treatments for PH-HFpEF. The company's plans to initiate a Phase 3 trial in 2023 also indicate progress in its product development.
The issuance of the patent provides Tenax Therapeutics with exclusive rights to develop and commercialize oral Levosimendan for the treatment of PH-HFpEF until 2040. This could potentially give the company a significant competitive advantage in a market with no current FDA-approved treatments. The initiation of a Phase 3 trial in 2023 also indicates progress in the company's product development, which could positively impact investor sentiment and the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100